WILMINGTON, N.C., July 28, 2011 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON) announced today it will participate in two investor conferences in August.
Ken Reali, President and Chief Executive Officer, and Joe Slattery, Executive Vice President and Chief Financial Officer, are scheduled to present at the 2011 Canaccord Genuity Growth Conference in Boston, MA on Thursday, August 11, 2011 at 10:30 a.m. ET and at the Wedbush Securities Life Sciences Conference in New York, NY on Wednesday, August 17 at 10:00 a.m. ET. They will discuss the Company and its progress toward gaining market share with its proprietary approach to treat degenerative conditions of the spine affecting the lower lumbar region and will also conduct one-on-one meetings with institutional investors. Investors that wish to request a meeting with TranS1 at either conference should contact Canaccord Genuity or Wedbush Securities.
About TranS1 Inc.
TranS1 is a medical device company focused on designing, developing and marketing products that implement its proprietary approach to treat degenerative conditions of the spine affecting the lower lumbar region. TranS1 currently markets the AxiaLIF family of products for single and multilevel lumbar fusion and the Vectre and Avatar posterior fixation systems for lumbar fixation supplemental to AxiaLIF fusion. TranS1 was founded in May 2000 and is headquartered in Wilmington, North Carolina. For more information, visit www.trans1.com.